PriceTargets.com logo

Turnstone Biologics - TSBX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 588.41%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.76 As of 04/26/2024 01:00 AM ET
▼ -0.14 (-4.83%)

This chart shows the closing price for TSBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Turnstone Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TSBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSBX

Analyst Price Target is $19.00
▲ +588.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Turnstone Biologics in the last 3 months. The average price target is $19.00, with a high forecast of $20.00 and a low forecast of $18.00. The average price target represents a 588.41% upside from the last price of $2.76.

This chart shows the closing price for TSBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Turnstone Biologics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2023Leerink PartnrsReiterated RatingMarket PerformLow
8/15/2023SVB SecuritiesInitiated CoverageMarket PerformLow
8/15/2023Bank of AmericaInitiated CoverageBuy$18.00Low
8/15/2023Piper SandlerInitiated CoverageOverweight$20.00Low
(Data available from 4/27/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/27/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Turnstone Biologics logo
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Read More

Today's Range

Now: $2.76
Low: $2.74
High: $3.04

50 Day Range

MA: $3.23
Low: $2.27
High: $5.48

52 Week Range

Now: $2.76
Low: $1.63
High: $13.20

Volume

130,089 shs

Average Volume

174,521 shs

Market Capitalization

$63.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Turnstone Biologics?

The following Wall Street sell-side analysts have issued stock ratings on Turnstone Biologics in the last year: Bank of America Co., Leerink Partnrs, Piper Sandler, and SVB Securities.
View the latest analyst ratings for TSBX.

What is the current price target for Turnstone Biologics?

2 Wall Street analysts have set twelve-month price targets for Turnstone Biologics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 588.4%. Piper Sandler has the highest price target set, predicting TSBX will reach $20.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $18.00 for Turnstone Biologics in the next year.
View the latest price targets for TSBX.

What is the current consensus analyst rating for Turnstone Biologics?

Turnstone Biologics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TSBX.

What other companies compete with Turnstone Biologics?

Other companies that are similar to Turnstone Biologics include Instil Bio, Precision BioSciences, Elutia, Ikena Oncology and JATT Acquisition. Learn More about companies similar to Turnstone Biologics.

How do I contact Turnstone Biologics' investor relations team?

The company's listed phone number is 347-897-5988 and its investor relations email address is [email protected]. The official website for Turnstone Biologics is turnstonebio.com. Learn More about contacing Turnstone Biologics investor relations.